DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Harrison SA, Neff G, Guy CD. et al.
Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis.
Gastroenterology 2021;
160 (01) 219.e1-231.e1
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.